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METHODS: Within the framework of an international project
(EUROCOST) Hospital Discharge Registers of 7 European
countries were analysed. To reduce heterogeneity, clinical inci-
dence was determined using different injury indicators, based on
a) health care use; b) anatomical criteria; or c) expected outcome.
The following existing and newly developed injury indicators
were tested: admissions excluding day cases (a), length of stay
4+ days and 7+ days (a), serious long-bone fractures (b), radio-
logical veriﬁable fractures (b), serious non-fatal injuries (c),
injuries with a moderate to high disability weight (Global Burden
of Disease weights and Dutch weights (IBIS)) (c). RESULTS:
Clinical injury incidence varied substantially in the rough data,
ranging from 6.6 to 22.9 per 1000 person years. Exclusion of
day cases and short-term admissions both led to an increased
variation in clinical incidence. The anatomical indicators
“serious long bone fractures” and “selected radiologically veri-
ﬁable fractures”, as well as both indicators based on disability
resulted in at least comparable variation in clinical incidence and
reduced variation in median length of stay in hospital as opposed
to the rough data. Contrary to rough data, those four indicators
showed reasonable (serious long bone fractures) to good associ-
ations with mortality rates. They were responsible for almost
equal parts of the hospital costs of injury (40–44%). CON-
CLUSIONS: Comparing only serious injuries with an objective
need for hospital admission based on disability weights (GBD
and IBIS) or on anatomical criteria (serious long bone fractures
and selected radiologically veriﬁable fractures) consistently
reduced the inﬂuence of registration and health care practices on
clinical incidence variation, which improved the comparability
of clinical injury incidence data.
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OBJECTIVES: To assess the contribution of prevention and
medical care to the improvement in population health, as part
of an overall assessment of the current cost-effectiveness of
health care. METHODS: We calculated the difference between
the current incidence, prevalence, and mortality of major health
problems, and those in a situation without prevention and
medical care (“partial null”). Major health problems include
among others infectious diseases, cancers and cardiovascular dis-
eases. The partial null was reconstructed with (if relevant his-
torical) data on disease-speciﬁc mortality, case fatality, incidence,
and knowledge of the natural history, combined with trend
analysis, and with relevant literature on e.g. the impact of antibi-
otics on infectious disease epidemiology. The separate impact of
prevention (predominantly screening, vaccination) and medical
care was disentangled by isolating the impact of changes in
(stage-speciﬁc) incidence on the one hand, and changes in case
fatality and stage-speciﬁc prevalence on the other hand. Histor-
ical changes in health behaviour (predominantly smoking) as a
possible result of public health interventions was included in a
subanalysis. Other behavioural changes, such as weight gain and
sexual behaviour, were regarded autonomous trends. All epi-
demiological data were age- and sex-speciﬁc. With multistate
lifetable modeling techniques the incidence, prevalence of disease
stages, disease-speciﬁc disability weights, and mortality were
combined to calculate disability adjusted life expectancy in the
current and null situation. RESULTS: Preliminary results will be
presented on infectious diseases and cancers. CONCLUSIONS:
Conclusions cannot yet be drawn. In a next step the results will
be combined with recent cost-of-illness data to calculate disease-
speciﬁc cost-effectiveness of prevention and medical care.
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Although standardisation of costing methodology is a prerequi-
site for the consistency and comparability of health economic
results it is often seen as insufﬁcient. There exist a number of
country-speciﬁc guidelines for the costing process in economic
evaluations, but they often stay vague, especially with regard 
to the empirically based valuation of resource consumption.
OBJECTIVE: To present a system of unit costs for the health
care system in Germany that reﬂects a societal perspective and
that ensures consistency and comparability of study results
between different intervention studies by following uniform val-
uation standards. METHODS: The valuation set is compatible
with the measurement of resource consumption derived from
patient reported data. Data sources for the valuation are registry
data, national statistics, charges and tariffs. The primary goal
was to approximate a national average by considering and
weighting different reimbursement schemes of private and public
health insurance. RESULTS: The valuation set includes all basic
direct and indirect cost components. As an example the valua-
tions for physician services are based on average reimbursement
per visit: A visit to the general practitioner is valued €15, costs
for visits to specialists range from €14 (psychiatrist) to €80 (radi-
ologist). Inpatient stays are valued by department-speciﬁc per
diem rates ranging form €260 (orthopaedics) to €481(neuro
surgery). Cost of a work day lost amount to €89 following a
human capital approach. The friction period when adopting the
friction cost approach is 72 days. CONCLUSIONS: The pro-
posed set of unit costs is based on average valuation of resource
consumption. As most cost components are not derived from
market prices but are based on administrative cost and/or remu-
neration data, institutional changes may have impact on the val-
uation of resource consumption. This should be considered when
empirical unit costs are updated.
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University of the Sciences, Philadelphia, PA, USA
OBJECTIVES: To compare and evaluate freeware options for
bootstrap analyses of incremental cost effectiveness data.
METHODS: Obenchain’s ICEplane software can be down-
loaded and installed from www.math.iupui.edu/~indyasa/
bobdown.htm. This software was compared against the web-
based bootstrap analyses available online at HealthStrategy.com.
Three datasets, that are downloadable from the ICEplane site,
were used in this software comparison. The three datasets are
from published studies dealing with abciximab (ABX), pindolol
(PIN) and tricyclic antidepressants (TCA). RESULTS: ICEplane
must be installed on MS Windows operating systems, in contrast
to the Health Strategy program that runs online through any
operating system with browsers including Internet Explorer,
Netscape or Firefox. Both software options provide output
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graphs such as scatter plots, conﬁdence intervals and accept-
ability curves. ICEplane and Health Strategy generated very
similar statistics on the initial raw data such as mean, median,
standard deviation and standard error. Bootstrapped statistics
include mean, median, incremental cost effectiveness ratio
(ICER), and 95% conﬁdence intervals. Respective mean ICERs
and conﬁdence intervals between ICEplane and Health Strategy
bootstraps on the three datasets were as follows: ABX: 3771 
(-665, 20,797) vs. 3692 (-1054, 13,303); PIN: -1880 (-412,
2863) vs. -1832 (-333, 25,442) and TCA: -16.48 (-169, 136)
vs. -19.96 (-221, 147). There was good agreement on Fieller’s
conﬁdence intervals. CONCLUSIONS: The ICEplane software
has more statistical and charting features than the Health Strat-
egy bootstrap program. The analyses from Health Strategy ran
more slowly with over 1000 bootstrap replications, but the
results obtained compare reasonably well to ICEplane. The
Health Strategy site has the potential beneﬁts of requiring no
installation and accessibility on multiple computer platforms.
Both of these freeware options should make it easier for indi-
viduals to explore basic bootstrap analyses of cost effectiveness
data, but more comprehensive statistical packages like Stata
should be used when possible.
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OBJECTIVES: Economic evaluations, such as cost effectiveness
analyses (CEA), of pharmaceuticals have historically focused on
costs and consequences at the individual level. However, illness
and individual-level health interventions affect both the individ-
ual and their family members. METHODS: While certain disci-
plines have assessed the cost of illness on multiple family
members and the effects of medical interventions on family
members, CEA has not routinely incorporated measures of effec-
tiveness and costs with the family as the unit of analysis. Family-
level CEA is consistent with recommendations that CEA should
consider everyone affected by the intervention and count all sig-
niﬁcant health outcomes and costs that ﬂow from it, regardless
of who experiences the outcomes or costs. RESULTS: Drawing
from methodologies recommended by the Panel on Cost Effec-
tiveness in Health and Medicine, we explore conceptual and
methodology issues related to estimating costs at the family level
for use in family-level CEA. CONCLUSIONS: We address the
challenges inherent in deﬁning a family, the availability of health
service data to link families, and methods for aggregating, eval-
uating, and comparing family-level costs.
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OBJECTIVES: To ﬁnd the optimal threshold in the cost-
effectiveness analysis in case of co-morbidities. METHODS: The
two-period model was constructed in which agent receives utility
from the income net of medical expenses. Agent can fall ill with
two illnesses in the ﬁrst period. The illnesses are treated and in
case of a success the agent survives to the second period. The
intensity of the treatment (the cost and the survival probability)
is subject to optimization maximizing the total utility. The ill-
nesses may have different morbidities and their occurrence can
be correlated. The relation between the cost of the treatment of
the i-th illness–Ci–and its efﬁciency–Pi–is described by increas-
ing and convex function Ci (Pi). The cases of exogenous and
endogenous budget (the expenses are covered by the insurer 
collecting a fair premium) are analysed. RESULTS: The results
are the same for the exogenous and the endogenous budget 
case. If the illnesses cannot occur together then the optimal
thresholds are the same for both illnesses irrespectively of 
the morbidities, C(P) functions or risk aversion. If the correla-
tion is equal to zero and the C(P) functions are equal then the
illness with higher morbidity will have a higher optimal C/E
threshold. More resources would be allocated to that illness 
both due to the higher morbidity and higher C/E threshold. 
If the correlation is equal to zero and the morbidities are equal
then the illness that is less costly to treat (i.e. always C¢i (Pi) 
< C¢j (Pj)) will have a lower optimal C/E ratio threshold. Similar
results are obtained for positive or slightly negative correlation.
When the correlation is sufﬁciently negative the reversal of 
the above-mentioned phenomena may occur. CONCLUSIONS:
The co-morbidities should be taken into consideration when
specifying the optimal threshold for the ratio in the cost-
effectiveness analysis, even when there is no correlation between
illnesses.
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